This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.

Inclusion Criteria:

• Type 2 diabetes in male or female patients
• Between 18 and 75 years of age
• With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization

Exclusion Criteria:

• Type 1 diabetics or type 2 diabetics currently on insulin therapy
• Patients unwilling or unable to discontinue their anti-diabetic medication(s)
• History of ketoacidosis
• History of therapy with rosiglitazone, troglitazone, pioglitazone